Focuses on developing therapies for hormone-driven cancers by targeting the androgen receptor pathway.
Context Therapeutics Inc., a pioneering clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focuses on advancing treatments for cancer in women across the United States. The company's flagship product candidate, onapristone extended release (ONA-XR), stands out as a potent antagonist of the progesterone receptor. This innovative therapy addresses resistance mechanisms observed in various classes of cancer treatments, particularly those targeting female hormone-dependent cancers such as anti-estrogen therapies.
In addition to ONA-XR, Context Therapeutics is actively developing CLDN6xCD3 bsAb, a novel bispecific monoclonal antibody. This antibody targets both CD3, a T-cell receptor, and Claudin 6 antigen, directing T-cell-mediated lysis specifically towards malignant cells expressing CLDN6. This approach holds promise for enhancing the efficacy of immunotherapies against gynaecologic cancers.
Founded in 2015, Context Therapeutics collaborates with Integral Molecular, Inc. on the development of their anti-Claudin 6 bispecific monoclonal antibody. This strategic partnership underscores Context Therapeutics' commitment to leveraging cutting-edge biotechnology to address critical unmet needs in cancer treatment, particularly for women battling hormone-dependent cancers.